Severe asthma: Pragmatic clinical lumping and time for investigational splitting

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 6, 2014, Pages 619-620

  Israel, Elliot ^a   Papi, Alberto ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IRRITANT AGENT; NITRIC OXIDE; STEROID; TRIAMCINOLONE;

ASTHMA; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE SEVERITY; EDITORIAL; ENVIRONMENTAL EXPOSURE; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SINUSITIS; WORLD HEALTH ORGANIZATION;

ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84896521799     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201402-0205ED     Document Type: Editorial

References (10)

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373.
2. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, et al. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-938.
3. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186:1102-1108.
4. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: Effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004;170: 601-605.
5. Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, Bousquet J, Chanez P. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001;107:73-80.
6. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011;365:119-126.
7. Romagnoli M, Caramori G, Braccioni F, Ravenna F, Barreiro E, Siafakas NM, Vignola AM, Chanez P, Fabbri LM, Papi A; ENFUMOSA Study Group. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007;37:552-557.
8. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-424.
9. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2008;179:19-24.
10. Bønnelykke K, Sleiman P, Nielsen K, Kreiner-Møller E, Mercader JM, Belgrave D, den Dekker HT, Husby A, Sevelsted A, Faura-Tellez G, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet 2014; 46:51-55.